Given its inhibitory activity against the PCSK9-LDLR interaction and its improved oral bioavailability (Fig. 1D) over compound 3f (28), NYX-PCSK9i was tested for its lipid-lowering properties as a monotherapy and in combination with atorvastatin in the APOE∗3-Leiden.CETP murine model of hyperlipidemia. Here, LDLR is linked to hyperlipidemia.